Venture-capital backed company developing an Innovative Cardiac Ablation system for the treatment of cardiac arrhythmias. Atrial Fibrillation (AF) is today a global epidemic with 33million people world-wide suffering from AF. AF patients have a 5 times greater risk of having a stroke and 3 times the risk of developing Heart Failure.
Patients with AF have significantly poorer quality of life when compared to healthy individuals, experiencing a variety of symptoms including lethargy, palpitations, dyspnea, chest tightness, sleeping difficulties and psychosocial distress. . Cardiac ablation is the interventional therapy of use with Radio Frequency and Cryo therapy the most common sources of energy. Argá Medtech SA is exploring the the use of Pulsed Field ablation and irreversible electroporation in subsitituion to current technologies, delivering a safer, faster and more effective therapy.
The most used technologies employed for cardiac ablation are RF (radio frequency) and Cryo. Usage has increased consistently over the past decades however success rate remains in the range of 50-70% depending on patient population.
These approaches are also associated with adverse events from the use of thermal energies. The utilization of thermal energy, destroys tissue indiscriminately increasing the risk of collateral injuries, such as oesophageal fistulas, pulmonary vein stenosis and phrenic nerve palsy.
The use of thermal energy may also increase the difficulty to ensure the correct dose of therapy is delivered.
Argá Medtech SA is exploring the use of Pulsed Field Ablation and irreversible electroporation, non-thermal sources of energy, to provide a safer and long lasting solution to the patients in need.
Argá Medtech SA
Route de la Corniche 4